Ipamorelin vs Sermorelin: GH Secretagogue Comparison
Ipamorelin and sermorelin both stimulate growth hormone release, but they do so through entirely different receptor systems. Sermorelin is a GHRH (growth hormone releasing hormone) analog that acts on GHRH receptors, while ipamorelin is a GHRP (growth hormone releasing peptide) that acts on ghrelin receptors. This distinction has practical implications for selectivity, dosing, and what other hormones are affected alongside GH.
This comparison is structured to highlight practical differences in research context, mechanisms, and use-case fit.
Ipamorelin
A pentapeptide ghrelin receptor agonist that stimulates GH release with the cleanest selectivity profile of any GHRP. Does not significantly elevate cortisol, prolactin, or ACTH. Developed by Novo Nordisk.
Sermorelin
A 29-amino acid analog of GHRH (the first 29 of 44 amino acids). Works through the GHRH receptor to trigger GH release. Has a long clinical history and was previously FDA-approved for GH deficiency diagnosis.
Side-by-Side Comparison
Use this table as a quick screening tool before reading the detailed sections below.
| Feature | Ipamorelin | Sermorelin |
|---|---|---|
| Receptor Target | GHS-R1a (ghrelin receptor) | GHRH receptor |
| Classification | GHRP (Growth Hormone Releasing Peptide) | GHRH analog (Growth Hormone Releasing Hormone) |
| Amino Acids | 5 | 29 |
| Cortisol Effect | None at standard doses | Minimal |
| Prolactin Effect | None at standard doses | Minimal |
| Hunger Stimulation | Mild (much less than GHRP-6) | None |
| GH Release Pattern | Amplifies natural pulses | Initiates GH release through natural pathway |
| Clinical History | Preclinical development (Novo Nordisk) | Previously FDA-approved (diagnostic use) |
GHRP vs GHRH: Different Pathways, Same Goal
The most important distinction is where each peptide acts. Sermorelin mimics the natural GHRH signal from the hypothalamus, telling pituitary somatotrophs to produce and release GH. Ipamorelin acts on ghrelin receptors on the same cells, providing a different stimulatory input. Because they use different receptors and signaling cascades, researchers sometimes study them together. The combination can produce a larger GH response than either alone because the signals are additive rather than competitive.
Selectivity Profiles
Ipamorelin's main advantage is its clean selectivity. It releases GH without affecting cortisol, ACTH, or prolactin levels, which is unique among GHRPs. GHRP-6 and GHRP-2, the older alternatives, significantly increase cortisol and cause intense hunger. Sermorelin also has a clean profile since GHRH naturally only targets GH release, but it can be less predictable in its dose-response because the GHRH receptor is more susceptible to desensitization with frequent dosing.
Practical Research Considerations
Sermorelin has the advantage of a longer clinical history and former FDA approval (for diagnostic purposes). This gives researchers a more established safety database. Ipamorelin, while never commercialized as a therapeutic, has extensive preclinical characterization by Novo Nordisk. For research requiring the most consistent GH output with minimal hormonal interference, ipamorelin is typically preferred. For protocols that aim to mimic the natural GH release axis as closely as possible, sermorelin is the more physiological choice.
The Verdict
Ipamorelin offers the cleanest GH release profile with no cortisol or prolactin effects. Sermorelin works through the more physiological GHRH pathway and has a longer clinical track record. The combination of both is a common research approach since they stimulate GH through complementary receptors. Choose based on whether selectivity or physiological mimicry is the higher priority.
Frequently Asked Questions
Can Ipamorelin and Sermorelin be studied together?
Yes, and this is a common research approach. They act on different receptors (ghrelin vs GHRH), so their GH-releasing effects are additive. The combination typically produces a larger and more sustained GH response than either alone.
Which causes fewer side effects?
Both have clean profiles compared to older GHRPs. Ipamorelin has the slight edge in selectivity data since it has been specifically shown to not affect cortisol, ACTH, or prolactin at GH-releasing doses.
Why was Sermorelin FDA-approved but not Ipamorelin?
Sermorelin was approved as a diagnostic agent for evaluating pituitary GH secretion capacity, not as a treatment. Novo Nordisk developed ipamorelin but chose not to pursue therapeutic commercialization.
Which produces more GH per dose?
At equivalent effective doses, ipamorelin and sermorelin produce similar peak GH levels. However, the combination of both produces significantly more GH than either alone.
Research Disclaimer
This comparison is for educational and informational purposes only. All information is based on published scientific research. Peptides sold by Peptrolix are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.
Research These Peptides
Open product pages for both compounds and compare variants, pricing, and availability.
View All PeptidesMore Comparisons
Keep exploring related matchups to validate your shortlist across multiple dimensions.
Related searches:
- ipamorelin vs sermorelin
- sermorelin vs ipamorelin
- best growth hormone peptide
- gh secretagogue comparison
- ipamorelin or sermorelin
- growth hormone releasing peptide
- ghrp vs ghrh
Start Your Research Today
All peptides 99%+ purity with certificates of analysis.
All compounds are supplied for laboratory and scientific research use only.
Shop Peptides